Abstract
Objective To define the characteristics and the outcome of myelitis associated with immune checkpoint inhibitors (ICIs).
Methods We performed a retrospective research in the databases of the French Pharmacovigilance Agency and the OncoNeuroTox network for patients who developed myelitis following treatment with ICIs (2011–2020). A systematic review of the literature was performed to identify similar cases.
Results We identified 7 patients who developed myelitis after treatment with ICIs (anti-PD1 [n = 6], anti-PD1 + anti-CTLA4 [n = 1]). Neurologic symptoms included paraparesis (100%), sphincter dysfunction (86%), tactile/thermic sensory disturbances (71%), and proprioceptive ataxia (43%). At the peak of symptom severity, all patients were nonambulatory. MRI typically showed longitudinally extensive lesions, with patchy contrast enhancement. CSF invariably showed inflammatory findings. Five patients (71%) had clinical and/or paraclinical evidence of concomitant cerebral, meningeal, caudal roots, and/or peripheral nerve involvement. Despite the prompt discontinuation of ICIs and administration of high-dose glucocorticoids (n = 7), most patients needed second-line immune therapies (n = 5) because of poor recovery or early relapses. At last follow-up, only 3 patients had regained an ambulatory status (43%). Literature review identified 13 previously reported cases, showing similar clinical and paraclinical features. All patients discontinued ICIs and received high-dose glucocorticoids, with the addition of other immune therapies in 8. Clinical improvement was reported for 10 patients.
Conclusion Myelitis is a rare but severe complication of ICIs that shows limited response to glucocorticoids. Considering the poor functional outcome associated with longitudinally extensive myelitis, strong and protracted immune therapy combinations are probably needed upfront to improve patient outcome and prevent early relapses.
Glossary
- CTLA4=
- cytotoxic T-lymphocyte-associated protein 4;
- ICI=
- immune checkpoint inhibitor;
- irAE=
- immune-related adverse event;
- NSCLC=
- non–small-cell lung cancer;
- PD-1=
- programmed death 1;
- PDL-1=
- programmed death-ligand 1
Immune checkpoint inhibitors (ICIs) are monoclonal antibodies used for cancer treatment that enhance host immune responses toward tumor cells by blocking signaling pathways responsible for T cell inhibition (cytotoxic T-lymphocyte-associated protein 4 [CTLA4], programmed death 1 [PD-1]/programmed death-ligand 1 [PDL-1]).1 Despite their remarkable oncological efficacy,1 ICIs might result in unwanted immune reactions against the self.2 Neurologic immune-related adverse events (irAEs) are relatively uncommon, but they might be severely disabling or even life threatening.3 Among them, myelitis seems especially rare, its description remaining limited to isolated cases. Here, we present 7 patients with ICI-related myelitis, together with a systematic review of the literature, with the aim to define the core characteristics and the outcome of this rare condition.
Methods
Present Series
We performed a retrospective research (July 2011–June 2020) in the database of the French Pharmacovigilance Agency and in the database of the OncoNeuroTox network (French network for neurologic complications from oncologic treatments) for cases of myelitis occurring during ICI treatment. Inclusion criteria comprised (1) symptoms of acute transverse myelitis (i.e., bilateral sensory, motor, or autonomic signs or symptoms attributable to spinal cord involvement, peaking between 4 hours and 21 days), (2) symptom onset within 3 months from the last dose of ICIs, (3) spinal cord lesions on MRI compatible with myelitis, and (4) exclusion of other causes of myelopathy (e.g., vascular, neoplastic, infectious, and compressive) after an extensive workup. Clinical and paraclinical data of the patients included in the study were gathered from referring centers and independently reviewed by 2 investigators (A.P. and D.P.). MRI scans were centrally reviewed by an expert neuroradiologist (S.A.). The French national commission for data protection and liberties approved the use of confidential, electronically processed, patient data (reference number 1922081).
Literature Review
We conducted a systematic MEDLINE research according to PRISMA guidelines for all articles published in English up to June 2020, reporting cases of myelitis during ICI treatment (appendix e-1, links.lww.com/NXI/A415). We identified 10 articles, reporting as many individual cases meeting the same inclusion criteria established for our series. Three additional cases were identified screening the proceedings of the AAN, EAN, and ECTRIMS congresses (2015–2020).
Data Availability
Additional data can be made available on request to the authors.
Results
Present Series
The main clinical and paraclinical features in our 7 patients are reported in table 1. The cases of 2 patients (patients #1, 4) are being submitted elsewhere as separate publications. Patients were receiving anti-PD1 (pembrolizumab [n = 3], nivolumab [n = 3]) or combination treatments (nivolumab plus ipilimumab [n = 1]) because of refractory (2/7, 29%) or metastatic (5/7, 71%) tumors consisting of non–small-cell lung cancer (NSCLC) in 5 cases. Three patients (3/7, 43%) had received thoracic irradiation involving the spinal cord.
Clinical and Paraclinical Features, Treatment, and Outcome in the 7 Cases of Myelitis Associated With ICI From Our Series
Symptoms of myelitis appeared after a median of 7 cycles of ICIs (range 3–51) and included moderate to severe paraparesis (7/7, 100%), sphincter dysfunction (6/7, 86%), tactile and/or thermic sensory deficits (5/7, 71%), and proprioceptive ataxia (3/7, 43%). At the peak of symptom severity, all patients were nonambulatory (median modified Rankin Scale score: 4).
Spine MRI showed longitudinally extensive lesions (i.e., ≥3 metameres) in 6 patients (6/7, 86%), often associated with spinal swelling (figure 1). Contrast enhancement was present in 6 cases (6/7, 86%) and was typically focal and patchy. In patients with a history of spinal irradiation, MRI alterations were primarily centered on irradiated metameres, although they clearly exceeded the radiation field.
(A) Spinal MRI at diagnosis in patient 3, showing multiple hyperintensities at C4-C5, T9-T11, and T12 on sagittal T2/STIR sequences, with focal areas of contrast enhancement on T1 sequences after gadolinium injection (circles). (B) Spinal and brain MRI at diagnosis in patient 4, who had positive antibodies to glial fibrillary acidic protein. Spinal MRI showed a faint hyperintensity at T10-T12 on T2/STIR sequences and a marked contrast enhancement of the anterior portion of the dural sac and of filum terminale on T1 sequences after gadolinium injection. Brain MRI in the same patient showed linear rims of contrast enhancement expanding radially from lateral ventricles. (C) Brain MRI at diagnosis in patient 7 showing small punctuate areas of contrast enhancement in bilateral subcortical and deep white matter, without corresponding signal alterations on FLAIR sequences (not shown). (D) Control spinal MRI of the thoracic tract (sagittal T2/STIR sequences) in patient 1, 15 days after starting treatment with high-dose glucocorticoids and plasmapheresis, showing an almost complete resolution of the longitudinally extensive hyperintensity of the spinal cord compared with initial imaging. (E) Control spinal MRI of the lumbar tract (sagittal T2/STIR and T1 sequences after gadolinium injection) in patient 7, 15 days after starting treatment with high-dose glucocorticoids, plasmapheresis, tocilizumab, and ruxolitinib, showing a marked reduction of the hyperintensity and swelling of the conus and of the associated leptomeningeal and caudal root enhancement compared with initial imaging. ICI = immune checkpoint inhibitor.
CSF analysis commonly showed inflammatory changes, including increased proteins (5/6; median protein levels 1.83 g/L, range 0.32–5.20 g/L), lymphocytic pleocytosis (4/6; median cell count 97 cells/mm3, range 3–900 cells/mm3), and CSF-specific oligoclonal bands (3/6).
Information on CNS autoantibody testing is provided in table e-1, links.lww.com/NXI/A418. One patient tested positive for antiglial fibrillary acidic protein antibodies in the CSF (patient #4), and 2 showed atypical neuronal reactivities on in-house indirect immunofluorescence on rodent brain sections (patient #1, 7) (figure e-1, links.lww.com/NXI/A416). Anti–aquaporin-4 and antimyelin oligodendrocyte glycoprotein antibodies were negative in all patients tested.
Besides signs and symptoms of acute transverse myelitis, 5 patients (5/7, 71%) had clinical, neurophysiologic, and/or radiologic evidence of concomitant brain (patients 4, 6, and 7) (figure 1), meningeal (patients 4 and 7), radicular (patients 1, 3, 6, and 7), and/or peripheral nerve (patient 6) involvement.
All patients discontinued ICI treatment at myelitis diagnosis and received high-dose glucocorticoids, associated with plasmapheresis in 1 (patient 4). One patient experienced a significant and sustained clinical benefit (patient 3), whereas 5 patients had to shift to second-line treatments because of poor recovery (patients 4, 5, and 7) or an early relapse at steroid tapering (patients 1 and 6; table 1). Second-line agents were started after a median of 20 days from symptom onset and included plasmapheresis (n = 3), cyclophosphamide (n = 2), IV immunoglobulin (IVIg, n = 1), natalizumab (n = 1), and an association of tocilizumab and ruxolitinib (n = 1). At last follow-up, a median of 6 months after diagnosis, only 3 patients had regained an ambulatory status (3/7, 43%). None of the patients was rechallenged with ICIs.
Literature Review
Our systematic literature review identified 13 previously published cases.e1-e13 Clinical and paraclinical features were similar to patients in our series (table 2), with contrast-enhancing longitudinally extensive lesions on MRI and inflammatory findings on CSF analysis. Four patients had positive CNS autoantibodies, including 2 with anti–aquaporin-4 antibodies.e3,e5,e9,e11 All patients discontinued ICIs and received high-dose glucocorticoids, alone (8/13, 62%) or in association with other immune therapies (5/13, 38%). Three patients (3/13, 23%) shifted to second-line treatments, including infliximab (n = 2), plasmapheresis (n = 2), and cyclophosphamide (n = 1). Clinical improvement was reported for 10 patients (10/13, 77%), 7 being ambulatory at last follow-up (7/9, 78%). Relapses were observed in 2 cases (2/13, 15%).e-7,e13 A single patient was rechallenged with ICIs, with no additional toxicity.e8
Main Clinical and Paraclinical Features in Patients With Acute Transverse Myelitis During ICI Treatment From Our Present Series and Literature Review
Discussion
Here, we reported 7 patients developing acute transverse myelitis following ICI treatment, which were identified through an extensive research in 2 independent national databases. Despite the limitations inherent to the retrospective nature of our methodology and the potential biases related to spontaneous notification,4 we could estimate that during the evaluated time frame, over 38,000 patients were treated with ICIs in France outside of clinical trials, making of ICI-related myelitis an extremely rare irAE.
Most patients in our series were affected by NSCLC, and almost half had received thoracic radiotherapy. Besides representing one of the most common indications to ICI treatment, NSCLC often requires the administration of local radiotherapy, which invariably delivers a dose to the spinal cord. By potentiating the immune responses elicited by ICIs,5 radiotherapy might indeed represent a predisposing factor to the development of myelitis.
Differently from other neurologic irAEs, myelitis was not invariably an early event. Clinical presentation was typical of acute transverse myelitis and was accompanied by inflammatory CSF findings and longitudinally extensive lesions on MRI. Of interest, in most cases, inflammatory changes extended to the brain parenchyma, the leptomeninges and caudal nerve roots, suggesting that it often exists a broader involvement of the nervous system that might have been underestimated in previous reports. A single patient in our series tested positive for known antibodies to neural antigens, although we recognize that screening for CNS antibodies was not always exhaustive (table e-1, links.lww.com/NXI/A418).
All patients in our series and in the literature received high-dose glucocorticoids as first-line treatment, as recommended by current guidelines,6 although most of them ultimately needed additional immune therapies because of the lack of functional improvement. This observation suggests that patients with longitudinally extensive myelitis might benefit from stronger upfront immune therapy schemes, as advocated for other threatening irAEs such as the myositis-myocarditis complex.7 Despite some data raised concern,8 glucocorticoid treatment does not seem to impair tumor control or patient survival9 and should be continued for at least 2 months6 to substantiate recovery and prevent early relapses.10 Targeted biological agents, such as natalizumab or tocilizumab, which have recently been experimented in this and other settings,7 should help to improve therapeutic results, without a risk of interfering with the antitumor activity of ICIs.
Study Funding
The authors report no targeted funding.
Disclosure
Go to Neurology.org/NN for full disclosures.
Acknowledgment
This publication uses data collected from all Regional Centers of Pharmacovigilance—organized in a French network of CRPV. The views expressed in this article are those of the authors and do not necessarily represent the ANSM position of the UMC or the World Health Organization. The information comes from a variety of sources, and the probability that the suspected adverse effect is drug related is not the same in all cases.
Appendix 1 Authors
Footnotes
Go to Neurology.org/NN for full disclosures. Funding information is provided at the end of the article.
The Article Processing Charge was funded by the authors.
- Received October 26, 2020.
- Accepted in final form January 7, 2021.
- Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg
► Watch
Topics Discussed
Alert Me
Recommended articles
Neurologic Adverse Events of Immune Checkpoint Inhibitors
Varied phenotypes and management of immune checkpoint inhibitor-associated neuropathies
Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer
Anti–Interleukin-6 and Janus Kinase Inhibitors for Severe Neurologic Toxicity of Checkpoint Inhibitors